Skip to main content
SpringerLink
Log in

Drug treatments: not always cost effective for urinary incontinence

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lenderking WR, Nackley JF, Anderson RB, et al. A review of the quality-of-life aspects of urinary urge incontinence. PharmacoEconomics 1996 Jan; 9(1): 11–23

    Article  PubMed  CAS  Google Scholar 

  2. Chutka DS, Fleming KC, Evans MP, et al. Urinary incontinence in the elderly population. Mayo Clin Proc 1996 Jan; 71: 93–101

    Article  PubMed  CAS  Google Scholar 

  3. Steel J, Fonda D. Minimising the cost of urinary incontinence in nursing homes. PharmacoEconomics 1995; 7(3): 191–7

    Article  PubMed  CAS  Google Scholar 

  4. Callahan CM. The costs of urinary incontinence. PharmacoEconomics 1994 Aug; 6: 183–5

    Article  PubMed  CAS  Google Scholar 

  5. Fantl JA, Cardozo L, McClish DK, et al. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994 Jan; 83: 12–8

    PubMed  CAS  Google Scholar 

  6. Brandberg Å, Mellström D, Perrson U, et al. Uro-genital oestrogen deficiency syndrome among women aged 65+: an assessment of the economics of its treatment. IHE working paper. The Swedish Institute for Health Economics, 1991

  7. Whittington R, Faulds D. Hormone replacement therapy: I. A pharmaco-economic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency. PharmacoEconomics 1994 May; 5(5): 419–45

    Article  PubMed  CAS  Google Scholar 

  8. Amin EA, Amin M. Comparison of the cost-effectiveness of various therapies for common prostatic disorders. PharmacoEconomics 1992 May; 1(5): 357–69

    Article  PubMed  CAS  Google Scholar 

  9. Finasteride: good tolerability but modest clinical benefit in BPH. Drug Ther Perspect 1993 Aug 30; 2 (4): 1–4

  10. Chirikos TN, Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol 1996 Apr; 155: 1311–16

    Article  PubMed  CAS  Google Scholar 

  11. Lowe FC, McDaniel RL, Chmiel JJ. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology 1996 Oct 46: 477–83

    Article  Google Scholar 

  12. Byrnes CA, Morton AS, Liss CL Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community-based study. Clin Ther 1995 Sep–Oct; 17: 956–69

    Article  PubMed  CAS  Google Scholar 

  13. Oxybutynin: a useful adjunct to behavioural therapy in detrusor instability. Drug Ther Perspect 1995 Jun 26; 5 (12): 5–7

  14. Schenelle JF, Keeler E, Hays RD, et al. A cost and value analysis of two interventions with incontinent nursing home residents. J Am Geriatr Soc 1995 Oct; 43: 1112–7

    Google Scholar 

  15. Fonda D, Woodward M, D’Astoli M, et al. Sustained improvement of subjective quality of life in older community-dwelling people after treatment of urinary incontinence. Age Ageing 1995 Jul; 24: 283–6

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drug treatments: not always cost effective for urinary incontinence. Drugs Ther. Perspect 7, 13–16 (1996). https://doi.org/10.2165/00042310-199607100-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607100-00005

Search

Navigation